Clear route to registration positions lucerastat as the potential first oral therapy for ...

February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat ...
The Malaysian Reserve

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately ...

As a next-generation selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily ...